市場調查報告書
商品編碼
1464966
腦腫瘤和脊髓癌市場:按腫瘤類型、治療方法和最終用戶分類 - 全球預測 2024-2030Brain & Spinal Cord Cancer Market by Tumor Type (Glioblastoma, Meningioma, Pituitary Tumors), Treatment (Diagnosis, Therapeutics), End-users - Global Forecast 2024-2030 |
※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。
預計2023年腦瘤和脊髓癌市場規模為37.7億美元,2024年達39.8億美元,預計2030年將達到55.9億美元,複合年成長率為5.75%。
腦癌和脊髓癌是當惡性(癌)細胞在腦或脊髓組織中生長時發生的中樞神經系統癌症。這些癌症會損害這些區域控制的重要功能,例如肌肉控制、感覺、記憶和其他認知能力。腦癌和脊髓癌的治療計劃根據每個人的具體情況量身定做,可能包括手術、放射線治療、化療、標靶治療或這些治療的組合。該市場的應用涵蓋各個醫學領域,包括神經腫瘤學、神經外科、放射學和安寧療護。最終使用者通常是需要診斷、治療和支持性護理服務的患者,以及醫院、診所和專門癌症治療中心等醫療機構。影響腦癌和脊髓癌治療需求的因素包括醫療技術的進步、腦癌和脊髓癌盛行率的上升、醫療基礎設施投資的增加以及對這些疾病的認知。然而,市場面臨某些挑戰,包括治療成本上升、獲得先進醫療設施的機會有限,以及對腦癌和脊髓癌複雜性的擔憂。另一方面,將人工智慧和機器學習引入診斷過程,以及人們對基於基因圖譜的個人化醫療的日益偏好,正在為腦腫瘤和脊椎癌市場創造潛在機會。
主要市場統計 | |
---|---|
基準年[2023] | 37.7億美元 |
預測年份 [2024] | 39.8億美元 |
預測年份 [2030] | 55.9億美元 |
複合年成長率(%) | 5.75% |
診斷是癌症治療的基石,準確的識別對於有效的治療策略至關重要。對於腦癌和脊髓癌,主要使用診斷影像和切片檢查。 電腦斷層掃描、MRI 和正子斷層掃描 (PET) 掃描等先進影像方式在診斷腦癌和脊髓癌方面發揮重要作用。切片檢查,包括針吸活體組織切片和開放切片檢查,透過分析組織樣本來確認癌症的存在。腦癌和脊髓癌的治療採用多方面的治療方法,包括手術、放射線治療、化療和標靶治療。手術通常是切除腫瘤的首選治療方法。另一種重要的治療方法是放射線治療,它使用高能量射線來破壞癌細胞。化療使用藥物殺死癌細胞,通常與其他治療方法結合。標靶治療是一種新型癌症治療方法,特異性針對癌細胞而不傷害正常細胞。根據腫瘤類型、分期和患者健康狀況,治療方法選擇是高度個人化的。對於局部腫瘤,優選手術或放射線治療來切除或縮小腫瘤。相反,化療和標靶治療有利於治療全身性疾病和無法手術的腫瘤。
門診手術中心 (ASC) 在腦癌和脊髓癌的治療中變得越來越重要,為患者提供恢復時間短的微創手術選擇。對於患者病情穩定且手術複雜程度為輕度至中度的病例,這些中心是首選。這些中心強調成本效益、病人便利性和快速出院。診斷中心在腦腫瘤和脊髓癌的早期診斷中發揮重要作用。這些設施配備了先進的診斷影像技術,包括 MRI、 電腦斷層掃描和 PET 掃描,這對於準確的診斷和治療計劃至關重要。患者和醫療保健提供者通常更喜歡提供先進技術、快速診斷時間和優質影像服務的專業診斷中心。醫院和診所是腦癌和脊髓癌患者最全面的醫療保健機構,提供從診斷到手術、放射線治療和化療等高級治療方法的廣泛服務。這些醫院因其交通方便、多學科團隊以及處理複雜病例和緊急情況的能力而受到青睞。儘管這三個領域在腦癌和脊髓癌患者的持續照護中都發揮著重要作用,但他們基於需求的偏好存在明顯差異。由於 ASC 的效率和成本效益,它是不太複雜的手術需求的首選。診斷中心對於使用先進的影像技術進行早期、準確的診斷至關重要。然而,醫院和診所處理最複雜和緊急的病例,提供最廣泛的服務,並擁有綜合多學科護理團隊的優勢。
區域洞察
美洲,特別是美國和加拿大,正在對研發進行大量投資,以推進腦癌和脊髓癌的治療。高昂的醫療成本以及大型醫療機構和生物技術公司的存在正在推動先進的研究舉措,包括精準醫學和新型療法。在南美洲,由於醫療成本上升、癌症發病率增加以及醫療基礎設施改善緩慢,巴西和阿根廷在腦癌和脊髓癌的治療方面進展緩慢。歐盟國家擁有強大的醫療基礎設施,多項癌症研究和早期檢測舉措正在進行中。公共和私營部門對醫學研究的資助不斷增加,正在帶來重大突破。該地區的患者受益於全民健康保險體系並獲得先進的治療。中東和非洲地區面臨獨特的挑戰,包括醫療基礎設施的變化和可近性問題。重點逐漸轉向改善醫療設施和癌症治療中心,政府和非政府組織扮演重要角色。在中國、日本和印度等國家經濟成長的推動下,亞太地區正見證醫療保健產業的快速轉型。這些國家的醫療支出正在快速成長,並且處於癌症治療技術創新的前沿。消費者對優質癌症照護的認知和需求很高,導致政府和私人對醫療基礎設施和研究計畫的投資增加。
FPNV定位矩陣
FPNV定位矩陣對於評估腦腫瘤和脊椎癌市場至關重要。我們檢視與業務策略和產品滿意度相關的關鍵指標,以對供應商進行全面評估。這種深入的分析使用戶能夠根據自己的要求做出明智的決策。根據評估,供應商被分為四個成功程度不同的像限:前沿(F)、探路者(P)、利基(N)和重要(V)。
市場佔有率分析
市場佔有率分析是一種綜合工具,可以對腦腫瘤和脊椎癌市場供應商的現狀進行深入而深入的研究。全面比較和分析供應商在整體收益、基本客群和其他關鍵指標方面的貢獻,以便更好地了解公司的績效及其在爭奪市場佔有率時面臨的挑戰。此外,該分析還提供了對該行業競爭特徵的寶貴見解,包括在研究基準年觀察到的累積、分散主導地位和合併特徵等因素。詳細程度的提高使供應商能夠做出更明智的決策並制定有效的策略,從而在市場上獲得競爭優勢。
1. 市場滲透率:提供有關主要企業所服務的市場的全面資訊。
2. 市場開拓:我們深入研究利潤豐厚的新興市場,並分析其在成熟細分市場的滲透率。
3. 市場多元化:提供有關新產品發布、開拓地區、最新發展和投資的詳細資訊。
4. 競爭評估和情報:對主要企業的市場佔有率、策略、產品、認證、監管狀況、專利狀況和製造能力進行全面評估。
5. 產品開發與創新:提供對未來技術、研發活動和突破性產品開發的見解。
1.腦腫瘤/脊髓癌市場的市場規模和預測是多少?
2.在腦腫瘤和脊髓癌市場的預測期內,有哪些產品、細分市場、應用和領域需要考慮投資?
3.腦腫瘤/脊髓癌市場的技術趨勢和法規結構是什麼?
4.腦腫瘤/脊髓癌市場主要廠商的市場佔有率是多少?
5.進入腦腫瘤/脊髓癌市場的合適型態和策略手段是什麼?
[187 Pages Report] The Brain & Spinal Cord Cancer Market size was estimated at USD 3.77 billion in 2023 and expected to reach USD 3.98 billion in 2024, at a CAGR 5.75% to reach USD 5.59 billion by 2030.
Brain and spinal cord cancers are types of central nervous system cancers that occur when malignant (cancer) cells grow in the brain or spinal cord tissue. These cancers can disrupt the vital functions controlled by these areas, including muscle control, sensation, memory, and other cognitive abilities. Treatment plans for brain and spinal cord cancers are tailored to each individual's specific condition and may include surgery, radiation therapy, chemotherapy, targeted therapy, or a combination of these. This market's applications span across various medical fields, including neuro-oncology, neurosurgery, radiology, and palliative care. End-users are typically healthcare facilities such as hospitals, clinics, and specialized cancer treatment centers, besides patients requiring diagnostic, therapeutic, and supportive care services. Factors influencing the need for brain and spinal cord cancer treatment include advancements in medical technology, rising prevalence of brain and spinal cord cancers, increased investment in healthcare infrastructure, and awareness about these conditions. However, the market faces certain challenges, such as high treatment costs, limited accessibility to advanced healthcare facilities, and concerns associated with the complex nature of brain and spinal cord cancers. On the other hand, the incorporation of AI and machine learning in diagnostic processes and increasing preference for personalized medicine based on genetic profile present potential opportunities for the brain and spinal cord cancers market.
KEY MARKET STATISTICS | |
---|---|
Base Year [2023] | USD 3.77 billion |
Estimated Year [2024] | USD 3.98 billion |
Forecast Year [2030] | USD 5.59 billion |
CAGR (%) | 5.75% |
Diagnosis forms the cornerstone of cancer treatment, with accurate identification pivotal for effective management strategies. For brain and spinal cord cancers, diagnosis primarily involves imaging techniques and biopsy procedures. Advanced imaging methods, including CT scans, MRI, and Positron Emission Tomography (PET) scans, play a vital role in diagnosing brain and spinal cord cancers. Biopsies, including needle biopsy and open biopsy, are employed to confirm the presence of cancer through tissue sample analysis. The therapy of brain and spinal cord cancers involves a multi-faceted therapeutic approach, including surgery, radiation therapy, chemotherapy, and targeted therapy. Surgery is often the first line of treatment aimed at tumor removal. Another critical treatment modality is radiation therapy, which employs high-energy rays to destroy cancer cells. Chemotherapy utilizes drugs to kill cancer cells and is often used in conjunction with other treatments. Targeted therapy represents a newer class of cancer treatment that specifically targets cancerous cells without harming normal ones. The selection of a therapeutic approach is highly individualized, based on tumor type, stage, and patient health. Surgery and radiation therapy are preferred for localized tumors to remove or decrease tumor size. In contrast, chemotherapy and targeted therapy are beneficial for managing systemic disease or tumors that are inoperable.
Ambulatory surgical centers (ASCs) have become increasingly important in the cure of brain and spinal cord cancer, offering patients minimally invasive surgery options with shorter recovery times. These centers are preferred for cases where the patient's condition is stable and the complexity of the surgery is low to moderate. They emphasize cost-effectiveness, patient convenience, and quick discharge. Diagnostic centers play a critical role in the initial stages of diagnosing brain and spinal cord cancer. These facilities are equipped with advanced imaging technologies including MRI, CT scans, and PET scans, vital for accurate diagnosis and treatment planning. Patients and healthcare providers often prefer specialized diagnostic centers for their advanced technology, quick turnaround times, and high-quality imaging services. Hospitals and clinics are the most comprehensive providers for brain and spinal cord cancer patients, offering various services from diagnosis to advanced treatment options, including surgery, radiation therapy, and chemotherapy. They are preferred for their accessibility, multidisciplinary teams, and ability to handle complex cases and emergencies. While all three segments play vital roles in the continuum of care for brain and spinal cord cancer patients, there are distinct differences in their need-based preferences. ASCs are preferred for their efficiency and cost-effectiveness for less complex surgical needs. Diagnostic centers are critical for early and accurate diagnosis, leveraging advanced imaging technologies. Hospitals and clinics, however, offer the broadest range of services, catering to the most complex and emergent cases, and have the advantage of integrated, multidisciplinary care teams.
Regional Insights
In the Americas, particularly in the United States and Canada, significant investments in research and development have been made to advance the treatment of brain and spinal cord cancers. High healthcare expenses and the presence of major healthcare institutions and biotech firms have propelled advanced research initiatives, including precision medicine and novel therapeutics. In South America, Brazil and Argentina are witnessing moderate development in the treatment of the brain and spinal cord cancer market due to rising healthcare expenditure, increasing incidence of cancer, and gradual improvements in healthcare infrastructure. The EU countries boast a robust healthcare infrastructure and several ongoing initiatives for cancer research and early detection. Increased funding from both public and private sectors towards healthcare research has led to significant breakthroughs. Patients in this region benefit from universal healthcare systems, influencing their ability to access advanced treatments. The Middle East and Africa region encounters unique challenges, including variable healthcare infrastructure and accessibility issues. The focus is gradually shifting towards improving healthcare facilities and cancer care centers, with several governments and NGOs playing a pivotal role. The APAC region is witnessing a rapid transformation in the healthcare sector, driven by growing economies such as China, Japan, and India. These countries have seen a surge in healthcare spending and are at the forefront of technological innovation in cancer treatment. Consumer awareness and demand for quality cancer care are high, leading to greater government and private investment in healthcare infrastructure and research initiatives.
FPNV Positioning Matrix
The FPNV Positioning Matrix is pivotal in evaluating the Brain & Spinal Cord Cancer Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Brain & Spinal Cord Cancer Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Key Company Profiles
The report delves into recent significant developments in the Brain & Spinal Cord Cancer Market, highlighting leading vendors and their innovative profiles. These include Amgen Inc., Bayer AG, bluebird bio, Inc., Bristol Myers Squibb Company, Dr. Reddy's Laboratories Ltd., Eisai Inc., F. Hoffmann-La Roche Ltd., Genentech, Inc., GlaxoSmithKline PLC, Illumina, Inc., Johnson & Johnson Services, Inc, Merck & Co., Inc., Nektar Therapeutics, Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals, Inc., Shimadzu Corporation, Siemens Healthineers, Teva Pharmaceutical Industries Ltd., and Y-mAbs Therapeutics A/S.
Market Segmentation & Coverage
1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.
1. What is the market size and forecast of the Brain & Spinal Cord Cancer Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Brain & Spinal Cord Cancer Market?
3. What are the technology trends and regulatory frameworks in the Brain & Spinal Cord Cancer Market?
4. What is the market share of the leading vendors in the Brain & Spinal Cord Cancer Market?
5. Which modes and strategic moves are suitable for entering the Brain & Spinal Cord Cancer Market?